Cost-Effectiveness of Annual Screening for Tuberculosis among Italian Healthcare Workers: A Retrospective Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
05 03 2020
Historique:
received: 26 01 2020
revised: 28 02 2020
accepted: 03 03 2020
entrez: 11 3 2020
pubmed: 11 3 2020
medline: 24 9 2020
Statut: epublish

Résumé

In the past few years, healthcare workers (HCWs) have been considered at higher risk for tuberculosis (TB) infection than the general population. On the other hand, recent studies have reported a low conversion rate among these workers. Recently, the Center for Disease Control (CDC) updated its recommendations, suggesting that an annual screening should not be performed in the absence of a documented exposure but only in workers with high-risk duties or with job tasks in settings at high risk of tuberculosis contagion (e.g., departments of infectious or pulmonary diseases). In fact, some studies showed that annual tuberculosis screening for all the HCWs was not cost-effective in countries with a low incidence of TB. In this study, we evaluated the conversion rate and the cost-effectiveness of two different tuberculosis screening strategies in a large population of Italian HCWs. In our retrospective study, we reviewed data coming from a tuberculosis screening conducted on 1451 HCWs in a teaching hospital of Rome. All workers were evaluated annually by means of the Quantiferon test (QFT) for a five-year period. Then, the conversion rate was calculated. We found a cumulative conversion rate of 0.6%. Considering the cost of the QFT test (48.26 euros per person), the screening of the HCWs resulted in a high financial burden (38,902.90 euros per seroconversion). Only one seroconversion would have been missed by applying the CDC updated recommendations, with a relevant drop of the costs: 6756.40 euros per seroconversion, with a global save of 296,075.10 euros. The risk of TB conversion among our study population was extremely low and it was related to the risk classification of the setting. Giving these results, the annual tuberculosis screening appeared to not be cost effective. We conclude that a targeted screening would be a better alternative in HCWs with a higher risk of TB exposure.

Sections du résumé

BACKGROUND
In the past few years, healthcare workers (HCWs) have been considered at higher risk for tuberculosis (TB) infection than the general population. On the other hand, recent studies have reported a low conversion rate among these workers. Recently, the Center for Disease Control (CDC) updated its recommendations, suggesting that an annual screening should not be performed in the absence of a documented exposure but only in workers with high-risk duties or with job tasks in settings at high risk of tuberculosis contagion (e.g., departments of infectious or pulmonary diseases). In fact, some studies showed that annual tuberculosis screening for all the HCWs was not cost-effective in countries with a low incidence of TB. In this study, we evaluated the conversion rate and the cost-effectiveness of two different tuberculosis screening strategies in a large population of Italian HCWs.
METHODS
In our retrospective study, we reviewed data coming from a tuberculosis screening conducted on 1451 HCWs in a teaching hospital of Rome. All workers were evaluated annually by means of the Quantiferon test (QFT) for a five-year period. Then, the conversion rate was calculated.
RESULTS
We found a cumulative conversion rate of 0.6%. Considering the cost of the QFT test (48.26 euros per person), the screening of the HCWs resulted in a high financial burden (38,902.90 euros per seroconversion). Only one seroconversion would have been missed by applying the CDC updated recommendations, with a relevant drop of the costs: 6756.40 euros per seroconversion, with a global save of 296,075.10 euros.
CONCLUSION
The risk of TB conversion among our study population was extremely low and it was related to the risk classification of the setting. Giving these results, the annual tuberculosis screening appeared to not be cost effective. We conclude that a targeted screening would be a better alternative in HCWs with a higher risk of TB exposure.

Identifiants

pubmed: 32150923
pii: ijerph17051697
doi: 10.3390/ijerph17051697
pmc: PMC7084819
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Respir Med. 2013 Apr;107(4):601-7
pubmed: 23312619
BMC Med. 2017 May 17;15(1):104
pubmed: 28514962
Open Forum Infect Dis. 2017 Aug 29;4(3):ofx137
pubmed: 28875155
MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):439-443
pubmed: 31099768
Arch Environ Occup Health. 2017 Mar 4;72(2):99-105
pubmed: 27018614
Thorax. 2012 Jan;67(1):62-70
pubmed: 21228420
J Hosp Infect. 2015 Feb;89(2):99-108
pubmed: 25559158
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87
pubmed: 24299555
Clin Infect Dis. 2018 Feb 10;66(5):706-711
pubmed: 29028965
J Occup Med Toxicol. 2009 Jan 09;4:1
pubmed: 19134168
Infect Control Hosp Epidemiol. 2012 Nov;33(11):1126-32
pubmed: 23041811
Biomed Res Int. 2017;2017:7538037
pubmed: 28337457
BMC Infect Dis. 2013 Sep 23;13:443
pubmed: 24059355
Open Respir Med J. 2019 Apr 30;13:1-4
pubmed: 31908683
Ig Sanita Pubbl. 2016 Mar-Apr;72(2):137-43
pubmed: 27336958
Clin Infect Dis. 2017 Jan 15;64(2):111-115
pubmed: 28052967
MMWR Recomm Rep. 2005 Dec 30;54(RR-17):1-141
pubmed: 16382216
PLoS One. 2013 Apr 04;8(4):e59546
pubmed: 23593145
BMC Infect Dis. 2014 Jun 12;14:324
pubmed: 24919953
Infect Control Hosp Epidemiol. 2004 Dec;25(12):1056-61
pubmed: 15636292

Auteurs

Luca Coppeta (L)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Giuseppina Somma (G)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Savino Baldi (S)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Elisabetta Tursi (E)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Iacopo D'Alessandro (I)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Andrea Torrente (A)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Stefano Perrone (S)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Antonio Pietroiusti (A)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Viale Montpellier 1, 00185 Roma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH